Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Showing matches for the individual search terms you entered. To search for an exact phrase, enclose your query in quotes.
Advanced filters
Search the full archive
Title matches

B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES (232 Online Views)

M. Talarico1|2, A. Cattabriga1|3, L. Pagnini1|4, V. Solli1|2, S. Barbato1|2, S. Ghibellini1|2, S. Masci1|2, E. Manzato1|2, M. Puppi1|2, M. Iezza1|2, K. Mancuso1|2, L. Pantani2, P. Tacchetti2, C. Terragna2, M. Ursi5, E. Maffini5, F. Bonifazi5, S. Brocchi3, C. Mosconi1|3, C. Nanni4, S. Fanti1|4, E. Zamagni1|2

1 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
3 Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
4 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
RRMM Functional Imaging T-cell Therapy
Text matches

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (121 Online Views)

First match: ... ecifically designed to serve as external control arms for comparison with novel therapies. A prior comparative analysis of MajesTEC-1 versus pooled LocoMMotion + MoMMent ...

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (152 Online Views)

First match: ... M) and true extramedullary disease (EMD) experience poor outcomes with standard therapies. The bispecific combination of talquetamab (Tal; anti-GPRC5D×CD3) and teclistama ...

M.V. Mateos1, P. Rodríguez-Otero2, S.Z. Usmani3, S. Kumar4, J.C. Ye5, S. Atrash6, H. Magen7, H. Quach8, M.P. Chu9, S. Trudel10, J. Richter11, H. Chuah12, M. Gatt13, E. Medvedova14, S. Raza15, D.H. Yoon16, T. Ishida17, J.V. Matous18, L. Rosiñol19, K. Onodera20, C. Maffucci21, E. Scott21, C. Heuck21, J. Zhang21, T. Henninger21, L. O’Rourke21, P. Thakkar21, M. Festa21, L. Huang21, J. Zhou21, M. Takamoto21, L. Pei21, J. Lu21, N. Au21, M. Krevvata21, Y.C. Cohen7

1 University Hospital of Salamanca, Spain
2 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Mayo Clinic Rochester, USA
5 University of Texas, Houston, USA
6 Levine Cancer Institute-Atrium Health, Charlotte, USA
7 Tel Aviv University, Israel
8 University of Melbourne, Australia
9 Alberta Health Services, Edmonton, Canada
10 Princess Margaret Cancer Centre, Toronto, Canada
11 Mount Sinai Medical Center, New York, USA
12 Royal Perth Hospital, Australia
13 Hebrew University of Jerusalem, Israel
14 Oregon Health and Science University, Portland, USA
15 Cleveland Clinic, USA
16 University of Ulsan College of Medicine, Seoul, Korea
17 Japanese Red Cross Medical Center, Tokyo, Japan
18 Colorado Blood Cancer Institute, Denver, USA
19 Hospital Clínic de Barcelona, Spain
20 Tohoku University Hospital, Sendai, Japan
21 Johnson & Johnson
Multiple Myeloma RedirecTT-1 trial RRMM

P33 | ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS (228 Online Views)

First match: ... quency and grade of infections were lower than those reported for BCMA-targeted therapies. These data support arlo-cel as a safe and effective potential early-line treatm ...

S. Bal1, M. Htut2, J. Berdeja3, L. Anderson4, A. Rossi5, T. Gregory6, L. Costa1, H. Hu7, Z. Guo7, J. Chen7, K. Jordahl7, N. Sarkis7, S. Ziyad7, W.M. Kao7, A. Kaeding7, M. Burgess7, O. Nadeem8

1 University of Alabama at Birmingham, USA
2 City of Hope Comprehensive Cancer Center, Duarte, USA
3 Greco-Hainsworth Tennessee Oncology Center for Research, Nashville, USA
4 Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, USA
5 Icahn School of Medicine at Mount Sinai, New York, USA
6 Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, USA
7 Bristol Myers Squibb, Princeton, USA
8 Dana-Farber Cancer Institute, Boston, USA
RRMM CAR-T cells BCMA

B10 | HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT (209 Online Views)

First match: ... s), two proteasome inhibitors (PIs), as well as BCMA- and GPRC5D-directed immunotherapies. This disease state can be termed “hepta-refractory“ MM, representing a newly em ...

C. Riedhammer1, M. Truger2, H. Lee3, L.B. Leypoldt4|5, M. Meggendorfer2, S. Hutter2, H. Müller2, J. Mersi1, S.K. Kadel1, T. Buchwald1, R. Kosch4, M. Helal6, N. Afrin6, A. Rosenwald7, E. Gerhard-Hartmann7, A. Brioli8|9, J. Krönke8, T. Haferlach2, C. Haferlach2, K.C. Weisel4, P. Neri3, H. Einsele1, K.M. Kortüm1, J.M. Waldschmidt1, N. Bahlis3, N. Weinhold10|11, L. Rasche1|6

1 Department of Internal Medicine 2, University Hospital of Würzburg, Germany
2 MLL Munich Leukemia Laboratory, Germany
3 Arnie Charbonneau Cancer Institute, University of Calgary, Canada
4 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Germany
5 Mildred Scheel Early Career Center, University Medical Center Hamburg-Eppendorf, Germany
6 Mildred Scheel Early Career Center, University Hospital Würzburg, Germany
7 Institute of Pathology, University of Würzburg, Germany
8 Department of Internal Medicine C, University Hospital of Greifswald, Germany
9 Hannover Medical School, Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Germany
10 Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Germany
11 Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center, Germany
Multiple myeloma Hepta-refractory Immunotherapy.

P55 | MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTER REAL WORLD EXPERIENCE (130 Online Views)

E. Manzato1|2, M. Puppi1|2, M. Talarico1|2, M. Iezza1|2, S. Masci1|2, S. Ghibellini1|2, A. Vitale2, S. Barbato1|2, P. Tacchetti1, L. Pantani1, K. Mancuso1|2, E. Zamagni1|2

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. A. Seràgnoli, Italy
2 Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy
Multiple Myeloma Neurological Toxicities RRMM

B05 | SPATIAL IMAGING UNLOCKS THE POTENTIAL OF CHARTING MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE (164 Online Views)

V. Desantis1, A. Andriano1, G. De Martino1, T. Düking2, O. Hartwig2, G. Ingravallo3, M. Biondo3, C. Botta4, R. Ria5, A. Vacca5, A.G. Solimando5

1 Department of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, Italy
2 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
3 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Italy
4 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
5 Internal Medicine "Guido Baccelli", University of Bari Aldo Moro, Italy
Spatial Imaging Plasma Cell Subclones Multiple Myeloma.

P75 | CURRENT STATUS OF REGISTRY OF MONOCLONAL GAMMOPATHIES - THE CZECH MYELOMA GROUP "REAL WORLD“ DATABASE (128 Online Views)

V. Maisnar1, L. Pour2, I. Spicka3, J. Minarik4, T. Jelinek5, A. Jungova6, P. Pavlicek7, L. Roziakova8, J. Radocha1, A. Heindorfer9, M. Sykora10, P. Kessler11, L. Stejskal12, M. Wrobel13, J. Kopeckova14, K. Stankova15, L. Pospisilova15, R. Hajek5

1 4th Department of Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic
2 Internal Hemato-Oncology Clinic, University Hospital, Brno, Czech Republic
3 1st Medical Department – Clinical Department of Haematology, General Teaching Hospital, Prague, Czech Republic
4 Department of Hematooncology, University Hospital, Olomouc, Czech Republic
5 Department of Clinical Hematology, University Hospital, Ostrava, Czech Republic
6 Department of Hemato-oncology, University Hospital, Plzen, Czech Republic
7 Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
8 Department of Clinical Hematology, University Hospital, Bratislava, Slovakia
9 Department of Hematology, Regional Hospital, Liberec, Czech Republic
10 Department of Clinical Hematology, Regional Hospital, Ceske Budejovice, Czech Republic
11 Department of Hematology, Regional Hospital, Pelhrimov, Czech Republic
12 Department of Hematology and Transfusion, Silesian Regional Hospital, Opava, Czech Republic
13 Department of Oncology, Regional Hospital, Novy Jicin, Czech Republic
14 Czech Myeloma Group, Brno, Czech Republic
15 Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Real-world Practice Monoclonal Gammopathies RMG Working Group

P72 | BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN TWO ACADEMIC BELGIAN CENTERS (117 Online Views)

M.C. Vekemans1, O. Rizzo2, N. Meuleman2

1 Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium
2 Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium
AL Amyloidosis Multiple Myeloma anti-BCMA

P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS (151 Online Views)

T. Shragai1|2, M. Ganayem1, Y. Cohen1|2, I. Avivi1|2, E. Lebel3|4, N. Even-Gross Zohar3|4, N. Melamed1, M. Gatt3|4

1 Tel-Aviv Sourasky Medical Center, Israel
2 Tel-Aviv University, Israel
3 Hadassah Medical Center, Jerusalem, Israel
4 Hebrew University, Jerusalem, Israel
Multiple Myeloma AL amyloidosis Talquetamab

P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE (142 Online Views)

E. Lebel1, A. Abdulgawad2, S. Bramanti3, G. Garate4, P.J. Ho5, M. Keränen6, Y. Cohen7, M. Vase8, A. Khot9, I. Kristensen10, R. Leblanc11, C. Lee12, W. Legiec13, H. Magen14, M.V. Mateos15, D. Oh16, L. Pour17, N. Schutz18, A. Spyridonidis19, K. Weisel20, J. Zaucha21, S. Larson22, A. Varshavsky-Yanovsky23, K. Grazioli24, D. Basudhar24, H. Hu24, Y. Meng24, L. Eldjerou24, S. Bal25, S. Harrison9, R. Popat26, M. Raab27, P. Rodriguez-Otero28

1 Hadassah Medical Center, Jerusalem, Israel
2 Christie NHS Foundation Trust, Manchester, UK
3 IRCCS Istituto Clinico Humanitas, Rozzano, Italy
4 Hospital Aleman, Buenos Aires, Argentina
5 Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia
6 Helsinki University Hospital, Finland
7 Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Israel
8 Aarhus Universitetshospital, Midtjylland, Denmark
9 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia
10 Odense Universitetshospital, Denmark
11 Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Quebec, Canada
12 Royal Adelaide Hospital, Australia
13 St. John of Dukla Oncology Center of Lublin Land,Poland
14 Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Israel
15 Hospital Universitario de Salamanca, Spain
16 Monash Health and Monash University, Clayton, Victoria, Australia
17 Masaryk University and University Hospital Brno, Czech Republic
18 Hospital Italiano de Buenos Aires, Argentina
19 University Hospital of Patras, Greece
20 University Medical Center Hamburg-Eppendorf, Germany
21 Medical University of Gdańsk and University Clinical Center, Poland
22 UCLA Medical Center, Los Angeles, USA
23 Fox Chase Cancer Center Temple Health, Philadelphia, USA
24 Bristol Myers Squibb, Princeton, USA
25 University of Alabama at Birmingham, USA
26 University College London Hospital, UK
27 Universitaetsklinikum Heidelberg, Germany
28 Clinica Universidad de Navarra, Pamplona, Spain
QUINTESSENTIAL-2 Trial Multiple Myeloma RRMM

P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE (109 Online Views)

G. Giunta1, C. Bellofiore2, E. Scalisi1, V. Del Fabro3, F. Elia1|2, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo1|2, A. Romano1|2, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy
3 Faculty of Medicine and Surgery, “Kore” University of Enna, Italy
Multiple myeloma Real-World Practice Sicily

P53 | NATIONWIDE EXPERIENCE WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL WORLD STUDY ON BEHALF OF THE GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO FOUNDATION (106 Online Views)

M. Puppi1|2|3, M. Pennisi4, F. Monaco5, L. Paris6, S. Aquino7, F. Ciceri8, M.C. Goldaniga9, M. Musso10, G. Buda11, M. Martino12, P. Chiusolo13, F. Fazio14, R. Mina15, F. Patriarca16, M.C. Tisi17, P. Tacchetti1, V. Marasco4, F. Ardizzoia1|2|3, M. Talarico1|2|3, K. Mancuso1|2|3, E. Maffini1, C. Carniti4, C. Terragna1, E. Zamagni1|2|3, F. Bonifazi1, M. Cavo2|3, P. Corradini4

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences
3 (DIMEC), University of Bologna, Italy
4 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan, Italy
5 AOSS Antonio e Biagio e Cesare Arrigo-SC Ematologia, Alessandria, Italy
6 ASST Papa Giovanni XXIII, Bergamo – SC Ematologia, Italy
7 Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy
8 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
9 Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
10 Dipartimento Oncologico "La Maddalena", UOC di Oncoematologia e TMO, Palermo, Italy
11 Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Italy
12 Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
13 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
14 Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Italy
15 AOU Città della Salute e della Scienza di Torino and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
16 Clinica Ematologica ed Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
17 Hematology Unit, San Bortolo Hospital, Vicenza, Italy
RRMM GIMEMA CAR-T

P52 | CILTACABTAGENE AUTOLEUCEL OUT-OF-SPECIFICATION MANUFACTURING OUTCOMES IMPROVE WITH EARLIER LINES OF THERAPY (121 Online Views)

R. Bowden1, H. Van Eeckhoutte1, G. Chow1, G. Choudhary1, L. Kallenbach1, V. Alegria1, M. Perciavalle2, J. Salmon2, J. Kang2, M. Mondon2, J. Vanak1, D. Ciccone1, P. Millili1, M. Onorata1, V. Plaks1, M. Merz3

1 Johnson & Johnson, USA
2 Legend Biotech USA Inc, Somerset, USA
3 Memorial Sloan Kettering Cancer Center, New York, USA
Ciltacabtagene autoleucel Multple Myeloma Manufacturing data

P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE (116 Online Views)

G. Giunta1, C. Bellofiore2, E. Scalisi1, F. Elia2|1, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo2|1, A. Romano2|1, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy

P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY (124 Online Views)

I. Vigliotta1, A. Varacalli1, M. Talarico1|2, M. Puppi1|2, S. Armuzzi2, B. Taurisano2, I. Pistis1, V. Solli2, V. M. Vuong2, E. Borsi1, A. Vitale1, G. Mazzocchetti3|4, A. Croce2, M. Martello1, A. Poletti2, M. Cavo2, E. Manzato1|2, E. Zamagni1|2, C. Terragna1

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences - University of Bologna, Italy
3 FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy
4 Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy
RRMM CAR-T Circulating plasma cells

P45 | MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES (137 Online Views)

Z.S. Najafabadi1, N. Afrin2, M. Helal2, H. Fischer1, M. John2, E. Stanojkovska1, J. Mersi1, S. Kadel1, J. Waldschmidt1, M. Kortüm1, K. Kretzschmar2, H. Einsele1, A. Riedel2, L. Rasche1|2

1 Internal Medicine II, Universitätsklinikum Würzburg, Germany
2 Mildred Scheel Early Career Centre for Cancer Research Würzburg, The Julius-Maximilians-Universität Würzburg, Germany
Multiple Myeloma Cancer cell dormancy 3D Model

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (148 Online Views)

R. Popat1, K. Uttervall2, K.M. Kortüm3, H. Magen4, M. Hansson5, T. Shragai6, E. Terpos7, C. T. Hansen8, S. Manier9|10, H. Gregersen11, Ø.M. Ottestad12, C. Touzeau13, E. Hatjiharissi14|15, S.L. Farmer16, E. Katodritou17, E. Spanoudakis18, M.Ø. Vase19, C. Liberatore20|21, M. Papathanasiou22, M.K. Angelopoulou7|23, E. Clavero24, R. Kittus25, P. Smirnov25, P. Hu25, D. Santra26, C. Albrecht25, E. Rubio-Azpeitia25, A. Perrot27

1 University College London Hospitals NHS Foundation Trust, UK
2 Karolinska University Hospital, Stockholm, Sweden
3 University Hospital of Würzburg, Germany
4 Tel-Aviv University, Israel
5 Sahlgrenska University Hospital, Gothenburg, Sweden
6 Tel-Aviv Sourasky Medical Center, Israel
7 National and Kapodistrian University of Athens, Greece
8 Odense University Hospital, Denmark
9 University of Lille, France
10 Centre Hospitalier Universitaire Lille, France
11 Aalborg University Hospital, Denmark
12 Akershus University Hospital, Lørenskog, Norway
13 University Hospital Hôtel-Dieu, Nantes, France
14 AHEPA University Hospital, Thessaloniki, Greece
15 Aristotle University of Thessaloniki, Greece
16 Vejle Hospital, Denmark
17 Theagenio Cancer Hospital, Thessaloniki, Greece
18 Democritus University of Thrace, Alexandroupolis, Greece
19 Aarhus University Hospital, Denmark
20 Santo Spirito Hospital, Pescara, Italy
21 "G d'Annunzio" University, Chieti, Italy
22 G Papanicolaou Hospital, Thessaloniki, Greece
23 Laiko General Hospital, Athens, Greece
24 Hospital Universitario Virgen De Las Nieves, Granada, Spain
25 Johnson and Johnson
26 Parexel International on behalf of Johnson & Johnson, Sheffield, UK
27 Université de Toulouse, France
REALiTEC-2 Trial RRMM Teclistamab

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (126 Online Views)

E. Searle1, V. Campbell2, C. Pawlyn3, D. Vogl4, S. Holstein5, S. Gooding6, M. Jenner7, T. Creasey8, A. Chaidos9, P. Rodríguez-Otero10, F. Al-Kaisi11, A. Brearton12, S. Moore6, J. O’Nions13, T. Somervaille1, T. Knurowski14, K. Clegg14, S. Paul14, K. Frese14, N. Joseph15

1 The Christie NHS Foundation Trust, Manchester, UK
2 Western General Hospital, Edinburgh, UK
3 The Royal Marsden NHS Foundation Trust, London, UK
4 Hospital of the University of Pennsylvania, Philadelphia, USA
5 University of Nebraska Medical Center, Omaha, USA
6 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
7 University Hospital Southampton NHS Foundation Trust, UK
8 Northern Centre for Cancer Care, Newcastle upon Tyne, UK
9 Imperial College Healthcare NHS Trust, London, UK
10 Clínica Universidad de Navarra, Pamplona, Spain
11 Royal Derby Hospital, UK
12 The Clatterbridge Cancer Centre, Liverpool, UK
13 University College London Hospital, UK
14 CellCentric Ltd, Cambridge, UK
15 Emory Winship Cancer Institute, Atlanta, USA
Multiple Myeloma Inobrodib RRMM

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (169 Online Views)

R. Popat1, K.M. Kortüm2, H. Magen3, V. Mykytiv4, C. Liberatore5, E. Zamagni6, M.C. Da Vià7, E. Antonioli8, M. Hansson9, D. Santra10, D. Greer10, K. Subrt11, P. Hu11, E. Aeby11, N. Francella11, N.M. Suñe11, A. Perrot12, K. Uttervall13

1 University College London Hospitals NHS Foundation Trust, UK
2 University Hospital of Würzburg, Germany
3 Tel Aviv University, Israel
4 Cork University Hospital, Ireland
5 Ospedale Santo Spirito, Pescara, Italy
6 University of Bologna, Italy
7 IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Careggi Hospital and University of Florence, Italy
9 Sahlgrenska University Hospital, Gothenburg, Sweden
10 Parexel International
11 Johnson & Johnson
12 Université de Toulouse, France
13 Karolinska University Hospital, Stockholm, Sweden
Multiple Myeloma REALiTAL Trial RRMM

P31 | PROGNOSTIC IMPACT OF INTERPHASE FISH IN MULTIPLE MYELOMA: SINGLE-CENTER IRISH EXPERIENCE (144 Online Views)

T. Pramod1, A. Bannaga1, S. Kumar1, B. Hennessy1, E. E. Hassadi1

1 University Hospital Waterford, Ireland
Multiple Myeloma Prognostic factors FISH abnormalities

P76 | DIFFERENT OUTCOMES OF t(11;14) MULTIPLE MYELOMA AND THERAPY-RELATED ACUTE UNDIFFERENTIATED LEUKEMIA TO VENETOCLAX-BASED THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION (129 Online Views)

V. Latal1, A. Kuba1, T. Pika1, M. Novak1, J. Balcarkova1, J. Navratilova1, M. Cernan1, T. Szotkowski1, J. Minarik1, T. Papajik1

1 Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
Multiple Myeloma Secondary malignancies Follow-up
1 - 22 of 22 items
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online